BJDX has 36-month beta value of 0.71. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for BJDX is 0.54M, and currently, short sellers hold a 0.08% ratio of that float. The average trading volume of BJDX on November 19, 2024 was 329.01K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
BJDX) stock’s latest price update
The stock price of Bluejay Diagnostics Inc (NASDAQ: BJDX) has surged by 12.69 when compared to previous closing price of 3.31, but the company has seen a -20.81% decline in its stock price over the last five trading sessions. globenewswire.com reported 2024-11-13 that ACTON, Mass., Nov. 13, 2024 (GLOBE NEWSWIRE) — Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings, today announced that the Company’s Board of Directors has approved a reverse stock split of its shares of common stock at a ratio of 1-for-50 (the “Reverse Stock Split”). The Reverse Stock Split will become effective at 12:01 a.m. Eastern Time on November 18, 2024, and the Company’s common stock will open for trading on The Nasdaq Capital Market on a post-split basis on November 18, 2024 under the Company’s existing trading symbol, “BJDX.” At such time, the Company’s common stock will also commence trading with a new CUSIP number, 095633509.
BJDX’s Market Performance
BJDX’s stock has fallen by -20.81% in the past week, with a monthly drop of -20.64% and a quarterly drop of -73.92%. The volatility ratio for the week is 26.12% while the volatility levels for the last 30 days are 28.88% for Bluejay Diagnostics Inc The simple moving average for the past 20 days is -21.54% for BJDX’s stock, with a -97.21% simple moving average for the past 200 days.
BJDX Trading at -35.93% from the 50-Day Moving Average
After a stumble in the market that brought BJDX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -99.76% of loss for the given period.
Volatility was left at 28.88%, however, over the last 30 days, the volatility rate increased by 26.12%, as shares sank -30.28% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -49.29% lower at present.
During the last 5 trading sessions, BJDX fell by -20.81%, which changed the moving average for the period of 200-days by -98.80% in comparison to the 20-day moving average, which settled at $4.7500. In addition, Bluejay Diagnostics Inc saw -99.24% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BJDX starting from Dey Svetlana, who purchase 500 shares at the price of $3.07 back on Dec 13 ’23. After this action, Dey Svetlana now owns 1,500 shares of Bluejay Diagnostics Inc, valued at $1,535 using the latest closing price.
Dey Indranil, the President and CEO of Bluejay Diagnostics Inc, purchase 500 shares at $3.27 during a trade that took place back on Dec 13 ’23, which means that Dey Indranil is holding 28,526 shares at $1,635 based on the most recent closing price.
Stock Fundamentals for BJDX
Current profitability levels for the company are sitting at:
- -5.57 for the present operating margin
- 0.89 for the gross margin
The net margin for Bluejay Diagnostics Inc stands at -5.93. The total capital return value is set at -1.11. Equity return is now at value -138.78, with -103.48 for asset returns.
Currently, EBITDA for the company is -9.17 million with net debt to EBITDA at 0.71. When we switch over and look at the enterprise to sales, we see a ratio of 65.39. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.26.
Conclusion
To put it simply, Bluejay Diagnostics Inc (BJDX) has had a bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
